<\/p>\n
Prazopress<\/strong> je Tableta s obsahem 1 mg prazosinu (s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm)<\/strong> od spole\u010dnosti Sun Pharma \u2014 selektivn\u00ed antagonista alfa-1 adrenergn\u00edho receptoru (chinazolinov\u00e1 struktura)<\/strong>, p\u016fsob\u00ed na post-synaptick\u00e9 alfa-1 adrenergn\u00ed receptory na hladk\u00e9m svalstvu tepen a \u017eil a na hladk\u00e9m svalstvu prostaty\/hrdla mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e<\/strong>. Prazosin byl uveden na trh spole\u010dnost\u00ed Pfizer v roce 1974 jako Minipress<\/strong> \u2014 prvn\u00ed selektivn\u00ed alfa-1 antagonist a p\u0159edloha pro celou t\u0159\u00eddu alfa-blok\u00e1tor\u016f. Okam\u017eit\u011b uvol\u0148ovan\u00fd prazosin byl v l\u00e9\u010db\u011b hypertenze z velk\u00e9 \u010d\u00e1sti nahrazen nov\u011bj\u0161\u00edmi t\u0159\u00eddami l\u00e9k\u016f, ale z\u016fst\u00e1v\u00e1 klinicky v\u00fdznamn\u00fd pro no\u010dn\u00ed m\u016fry spojen\u00e9 s PTSD<\/strong> (mimo schv\u00e1len\u00e9 indikace) a pro vybran\u00e9 p\u0159\u00edpady benign\u00ed hyperplazie prostaty (BPH). Polo\u010das 2-3 hodiny (kr\u00e1tk\u00fd \u2014 vy\u017eaduje d\u00e1vkov\u00e1n\u00ed dvakr\u00e1t a\u017e t\u0159ikr\u00e1t denn\u011b); n\u00e1stup \u00fa\u010dinku 30-90 minut; maxim\u00e1ln\u00ed plazmatick\u00e1 koncentrace 1-3 hodiny; d\u00e9lka \u00fa\u010dinku 4-10 hodin v z\u00e1vislosti na d\u00e1vce. Hlavn\u00ed indikace: no\u010dn\u00ed m\u016fry spojen\u00e9 s PTSD (mimo schv\u00e1len\u00e9 indikace; hlavn\u00ed modern\u00ed pou\u017eit\u00ed), rezistentn\u00ed hypertenze jako dopl\u0148kov\u00e1 l\u00e9\u010dba, benign\u00ed hyperplazie prostaty<\/strong>. Typick\u00e9 d\u00e1vkov\u00e1n\u00ed: Hypertenze:<\/strong> za\u010d\u00e1tek 0,5-1 mg p\u0159ed span\u00edm<\/strong> pro prvn\u00ed d\u00e1vku (\u201cfenom\u00e9n prvn\u00ed d\u00e1vky\u201d \u2014 viz n\u00ed\u017ee), pot\u00e9 1 mg 2-3kr\u00e1t denn\u011b, s titrac\u00ed na 2-20 mg\/den v rozd\u011blen\u00fdch d\u00e1vk\u00e1ch. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> Studie ALLHAT p\u0159ed\u010dasn\u011b ukon\u010dila v\u011btev s doxazosinem kv\u016fli nadm\u011brn\u00e9mu v\u00fdskytu srde\u010dn\u00edho selh\u00e1n\u00ed, co\u017e vedlo k tomu, \u017ee modern\u00ed doporu\u010den\u00ed rezervuj\u00ed alfa-blok\u00e1tory jako l\u00e9ky \u010dtvrt\u00e9\/p\u00e1t\u00e9 volby u rezistentn\u00ed hypertenze. V\u017edy pod\u00e1vejte prvn\u00ed d\u00e1vku p\u0159ed span\u00edm<\/strong> \u2014 fenom\u00e9n \u201cprvn\u00ed d\u00e1vky\u201d zp\u016fsobuje z\u00e1va\u017enou ortostatickou hypotenzi v po\u010d\u00e1te\u010dn\u00edch hodin\u00e1ch. Nen\u00ed prvn\u00ed volbou antihypertenziv (obavy z t\u0159\u00eddy ALLHAT) \u2014 vyhrazeno pro \u010dtvrtou\/p\u00e1tou linii, zejm\u00e9na tam, kde se vyskytuje BPH. U v\u011bt\u0161iny hypertonik\u016f modern\u00ed l\u00e9\u010dba za\u010d\u00edn\u00e1 ACE inhibitorem\/ARB, blok\u00e1torem kalciov\u00fdch kan\u00e1l\u016f, thiazidem a spironolaktonem, ne\u017e se p\u0159istoup\u00ed k alfa-blok\u00e1toru nebo centr\u00e1ln\u011b p\u016fsob\u00edc\u00edmu \u010dinidlu.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Prazopress jsou peror\u00e1ln\u00ed tablety Prazosinu (s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm) 1 mg od Sun Pharma, dod\u00e1van\u00e9 v balen\u00ed po 30-90 tablet\u00e1ch. Prazosin byl uveden na trh spole\u010dnost\u00ed Pfizer v roce 1974 jako Minipress<\/strong> \u2014 prvn\u00ed selektivn\u00ed alfa-1 antagonist a p\u0159edloha pro celou t\u0159\u00eddu alfa-blok\u00e1tor\u016f. Okam\u017eit\u011b uvol\u0148ovan\u00fd prazosin byl v l\u00e9\u010db\u011b hypertenze z velk\u00e9 \u010d\u00e1sti nahrazen nov\u011bj\u0161\u00edmi t\u0159\u00eddami l\u00e9k\u016f, ale z\u016fst\u00e1v\u00e1 klinicky v\u00fdznamn\u00fd pro no\u010dn\u00ed m\u016fry spojen\u00e9 s PTSD<\/strong> (mimo schv\u00e1len\u00e9 indikace) a pro vybran\u00e9 p\u0159\u00edpady benign\u00ed hyperplazie prostaty (BPH).<\/p>\n Prazosin (s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm) p\u016fsob\u00ed na post-synaptick\u00e9 alfa-1 adrenergn\u00ed receptory na hladk\u00e9m svalstvu tepen a \u017eil a na hladk\u00e9m svalstvu prostaty\/hrdla mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e<\/strong>. N\u00e1sledn\u00e9 \u00fa\u010dinky:<\/p>\n Kl\u00ed\u010dov\u00e9 d\u016fkazy z klinick\u00fdch studi\u00ed:<\/strong> VA Cooperative Trial (1982)<\/strong> \u2014 prazosin comparable to standard antihypertensives in mild-moderate hypertension; established clinical validity. ALLHAT doxazosinov\u00e1 v\u011btev (2000)<\/strong> \u2014 terminated 3 years early due to 25% excess risk of heart failure vs chlorthalidone; interpreted as a class concern for alpha-blockers in HTN. Raskind et al. PTSD trials (2003, 2007, 2013)<\/strong> \u2014 prazosin 1-10 mg at bedtime initially, titrating by 1 mg every 3-5 days to clinical effect. Typical effective dose 2-10 mg at bedtime; some patients require 15-20 mg. Evidence base: Raskind and Peskind RCTs (2003-2013) showed significant reduction in nightmare frequency and improvement in sleep architecture, though the larger 2018 PACT trial was negative \u2014 enthusiasm tempered but use remains common when CBT-I and trauma-focused psychotherapy are inadequate. Prazopress Dosage<\/strong> PTSD nightmares (off-label):.<\/p>\n Z\u00e1kladn\u00ed d\u00e1vka:<\/strong> Hypertenze:<\/strong> za\u010d\u00e1tek 0,5-1 mg p\u0159ed span\u00edm<\/strong> pro prvn\u00ed d\u00e1vku (\u201cfenom\u00e9n prvn\u00ed d\u00e1vky\u201d \u2014 viz n\u00ed\u017ee), pot\u00e9 1 mg 2-3kr\u00e1t denn\u011b, s titrac\u00ed na 2-20 mg\/den v rozd\u011blen\u00fdch d\u00e1vk\u00e1ch. Nen\u00ed l\u00e9kem prvn\u00ed volby p\u0159i hypertenzi.<\/strong> Studie ALLHAT p\u0159ed\u010dasn\u011b ukon\u010dila v\u011btev s doxazosinem kv\u016fli nadm\u011brn\u00e9mu v\u00fdskytu srde\u010dn\u00edho selh\u00e1n\u00ed, co\u017e vedlo k tomu, \u017ee modern\u00ed doporu\u010den\u00ed rezervuj\u00ed alfa-blok\u00e1tory jako l\u00e9ky \u010dtvrt\u00e9\/p\u00e1t\u00e9 volby u rezistentn\u00ed hypertenze.<\/p>\n Dal\u0161\u00ed indikace:<\/strong> Prazopress Dosage<\/strong> PTSD nightmares (off-label):. 1 mg at bedtime initially, titrating by 1 mg every 3-5 days to clinical effect. Typical effective dose 2-10 mg at bedtime; some patients require 15-20 mg. Evidence base: Raskind and Peskind RCTs (2003-2013) showed significant reduction in nightmare frequency and improvement in sleep architecture, though the larger 2018 PACT trial was negative \u2014 enthusiasm tempered but use remains common when CBT-I and trauma-focused psychotherapy are inadequate.<\/strong> Benign prostatic hyperplasia:. 1-2 mg two or three times daily; extended-release prazosin (XL) is generally preferred for BPH.<\/strong> Raynaud phenomenon:.<\/p>\n Pod\u00e1v\u00e1n\u00ed:<\/strong> 1-5 mg two or three times daily off-label.<\/p>\n Monitorovac\u00ed pl\u00e1n:<\/strong><\/p>\n Ukon\u010den\u00ed l\u00e9\u010dby:<\/strong> \u017e\u00e1dn\u00fd rebound syndrom. Alfa-blok\u00e1tory lze vysadit, ale o\u010dek\u00e1vejte ur\u010dit\u00fd vzestup TK, pokud v\u00fdznamn\u011b p\u0159isp\u00edvaly k jeho kontrole. P\u0159i op\u011btovn\u00e9m nasazen\u00ed po p\u0159eru\u0161en\u00ed >1 t\u00fddne za\u010dn\u011bte od po\u010d\u00e1te\u010dn\u00ed d\u00e1vky (ne od p\u0159edchoz\u00ed udr\u017eovac\u00ed d\u00e1vky) \u2014 fenom\u00e9n prvn\u00ed d\u00e1vky se vrac\u00ed.<\/p>\n \u010cast\u00e9 (>1 %):<\/strong><\/p>\n Nep\u0159\u00edli\u0161 \u010dast\u00e9, ale klinicky v\u00fdznamn\u00e9:<\/strong><\/p>\n T\u011bhotenstv\u00ed:<\/strong> vyvarujte se \u2014 omezen\u00e9 \u00fadaje o t\u011bhotenstv\u00ed u alfa-blok\u00e1tor\u016f. P\u0159i hypertenzi v t\u011bhotenstv\u00ed p\u0159ejd\u011bte na methyldopu, labetalol nebo nifedipin.<\/p>\n Kojen\u00ed:<\/strong> omezen\u00e9 \u00fadaje; pou\u017e\u00edvejte s opatrnost\u00ed. Pokud mo\u017eno p\u0159ejd\u011bte na l\u00e9k s lep\u0161\u00edmi \u00fadaji o kojen\u00ed (labetalol, nifedipin, enalapril).<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
Co je Prazopress?<\/h2>\n
Jak Prazosin (s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm) funguje<\/h2>\n
\n
Schv\u00e1len\u00e9 a v\u011bdecky podlo\u017een\u00e9 indikace<\/h2>\n
\n
1 mg at bedtime initially, titrating by 1 mg every 3-5 days to clinical effect. Typical effective dose 2-10 mg at bedtime; some patients require 15-20 mg. Evidence base: Raskind and Peskind RCTs (2003-2013) showed significant reduction in nightmare frequency and improvement in sleep architecture, though the larger 2018 PACT trial was negative \u2014 enthusiasm tempered but use remains common when CBT-I and trauma-focused psychotherapy are inadequate.<\/h2>\n
\n
take with or without food. First dose at bedtime. Regular doses spread 6-8 hours apart.<\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n
\n
\n
Kontraindikace<\/h2>\n
\n
Interakce s l\u00e9\u010divy<\/h2>\n
\n
M\u00edsto p\u0159\u00edpravku Prazopress v antihypertenzn\u00ed hierarchii<\/h2>\n